Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Nicholas C. Turner(Royal Marsden Hospital), Igor Bondarenko(Dnipro State Medical University), Jungsil Ro(National Cancer Center), Seock‐Ah Im(Seoul National University Hospital), Norikazu Masuda(Osaka National Hospital), Marco Colleoni(European Institute of Oncology), Angela DeMichele(University of Pennsylvania), Sherene Loi(Peter MacCallum Cancer Centre), Sunil Verma(University of Calgary), Hiroji Iwata(Aichi Cancer Center), Nadia Harbeck(Ludwig-Maximilians-Universität München), Ke Zhang(Pfizer (United States)), Kathy Puyana Theall(Pfizer (United States)), Yuqiu Jiang(Pfizer (United States)), Cynthia Huang Bartlett(Pfizer (United States)), María Koehler(Pfizer (United States)), Dennis J. Slamon(University of California, Los Angeles)
The Lancet Oncology
March 2, 2016
10.1016/s1470-2045(15)00613-0
Cited by 1,815

Abstract

Related Papers

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
Nicholas C. Turner, Jungsil Ro, Fabrice André et al.|New England Journal of Medicine|2015|1.6k
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy, Yang Shen, Helen Won et al.|Nature Genetics|2013|1.3k
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortés, Joyce O’Shaughnessy, David Loesch et al.|The Lancet|2011|1.1k
Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations
Devin Dressman, Hai Yan, Giovanni Traverso et al.|Proceedings of the National Academy of Sciences|2003|829
Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6
Peter L. Toogood, Patricia J. Harvey, Joseph T. Repine et al.|Journal of Medicinal Chemistry|2005|503